NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva
Ensuring the best treatments within a public health approach Optimizing of what we have Ensuring access Looking ahead
Ensuring the best treatments within a public health approach Optimizing of what we have Ensuring access Preparing for the future
Optimizing ART for adults: Conference on Drug Optimization Crawford et al, Lancet ID 2012 Ford et al, Current Opinions 2013 Vitoria et al, JIAS [in press] Improved API synthesis 3TC vs FTC EFV in pregnancy TDF+XTC+EFV remain WHO first choice Dose optimizationPotential of Dolutegravir DTG + EFV 400 mg Long acting formulations Improved formulations of LPV/r for children TDF vs TAF Dual therapy
PHTI-Paediatric Treatment Initiative
Commitment to Action: Stakeholders contribution to 6 core objectives Objective Main Participating Organizations Accelerate the development of high priority pediatric ART formulations PHTI, WHO, originator and generic drug manufacturers Support rapid and streamlined regulatory approval for pediatric ARVs FDA, WHO Ensure that new formulations are promptly eligible for procurement PAPWG, Global Fund Ensure demand forecasts and market sizing data on priority products WHO, UNAIDS, CHAI Track financing commitments for procurement of pediatric ARVs PEPFAR, Global Fund, UNITAID, PAPWG Support demand creation and uptake of pediatric ART formulations CHAI, IATT, PEPFAR
Ensuring access: price variations for ART Lowest price (U$)Highest Price (U$)Median Price (U$) TDF/FTC/EFV TDF/3TC/EFV AZT/3TC/NVP LPV/r ATV/r RAL DRV AMDS, 2015
Integrase inhibitors for 1 st & 2 nd line DTG and TAF for children Induction/maintenance Long acting agents Strategies or regimen for stable patients Preparing for the future
LATTE STUDY: VIROLOGIC SUCCESS DURING INDUCTION AND MAINTENANCE PHASES
Acknowledgements Marco Vitoria Meg Doherty Vincent Habiyambere Ed Mills Steve Kanters Martina Penazzato